From the Editor

Nov 01, 2002
Pharmaceutical Executive
PR is more than free ink. It is even more than good free ink.
Oct 01, 2002
Pharmaceutical Executive
I was wondering whether I could take any more pain, when the moment slowed to a crawl. Pain wakened fear. Eternity lingered alongside. Mortality, grinning over my shoulder, blew a chill breath across the nape of my neck. "Dying would end the pain," I thought. "But I don't want to die like this."
Sep 01, 2002
Pharmaceutical Executive
Sixteen years ago I began to edit Pharmaceutical Executive, a magazine unknown to me only a few months before. Today, I wonder how much I've learned in all the time since.
Aug 01, 2002
Pharmaceutical Executive
Just when pharma companies finally awake to the need for a good reputation, the stakes go vertical. The long-perceived and possibly illusory gap between shareholder behavior and public outrage suddenly disappears. And each company stands or falls on its revealed record.
Jul 01, 2002
Pharmaceutical Executive
This season, boosterism is out; hedging is in. Yet a realistic assessment of the pharma market, even under the shadow of terror and war, reveals new opportunities. For every ominous sign or setback, a potential line of offense exists. Despite the press of a slow economy, nervous investors, customer consolidation, and cost-shifting in healthcare, the industry remains rich in resources, growth, and opportunity. Here are some of the market forces, issues, and opportunities for the pharma universe this year:
Jun 01, 2002
Pharmaceutical Executive
Question: When does the Right mirror the Left?And they are. Answer: When they're both attacking the pharmaceutical industry.
May 01, 2002
Pharmaceutical Executive
Science deserves all the credit it gets, and more, for driving this industry. Still, no science succeeds without a certain application of what we broadly call art. Inside the scientific discipline, many arts apply-the art of experiment, the art of planning, and the art of free association among them.
Apr 01, 2002
Pharmaceutical Executive
Perseverance furthers. Those two unadorned words from the ancient I Ching were all that first entered my startled mind as I accepted the Oscar of business-to-business media-the Grand Neal Award.
Mar 01, 2002
Pharmaceutical Executive
How quickly the promise of pharmacogenomics and other medical miracles materializes may soon depend more on war-driven politics than science. Only free exchange of scientific information in public arenas such as peer-review journals makes progress possible. But now in the United States, long an avatar of freedom and progress, the government's war on terror threatens to subjugate that tradition in a new culture of secrecy.
Feb 01, 2002
Pharmaceutical Executive
Who, or what, creates wealth? Answering that question has become as much political football as economic theory. Last month, the US president reminded us that government does not make wealth but, at best, fosters a climate conducive to it. The old-left idea that workers create and should share equally in the fruits of production has long since died of exhaustion. By process of elimination, the only apparent answer remaining belongs to idealistic capitalists, who herald the enterprising companies from which all wealth "obviously" flows-for most of us, as paychecks.
native1_300x100
lorem ipsum